Diabetes can affect many parts of the body, but two complications often travel together: diabetic eye disease and diabetic kidney disease. Both are shaped by long-term metabolic stress and injury to small blood vessels. Researchers have long suspected that they may also share deeper biological pathways.
A new PLOS Biology study offers a detailed clue about one possible pathway. The researchers found that high-glucose stress may worsen damage in the retina and kidneys by disrupting tiny cell structures called primary cilia. In diabetic mice, blocking parts of a molecular loop involving PRMT1 and HDAC6 helped preserve cilia and improved disease-related measures in both tissues.
That is promising science. It is not yet a treatment for people with diabetes.
The most practical message today is not to seek an experimental inhibitor. It is to protect the eyes and kidneys with the tools already available: regular screening, individualized glucose and blood-pressure care, kidney-protective treatment when appropriate, and attention to the daily conditions that shape health.
What are primary cilia—and why do they matter?
Primary cilia are small, antenna-like structures that project from the surface of many cells. They help cells sense and respond to signals from their surroundings. In the eye and kidney, they are involved in functions that help tissues maintain structure and respond to stress.
In the new study, researchers examined the effect of hyperglycemic stress—conditions of elevated glucose—on cilia in retinal and kidney tissues. They reported that two proteins, PRMT1 and HDAC6, increased under high-glucose conditions. Together, these proteins formed a feedback loop that promoted cilia disassembly. In the study’s diabetic-mouse models, genetic disruption of either enzyme preserved ciliary architecture and improved measures related to retinal and kidney injury. Pharmacological inhibition of the loop also reduced disease-related features in the models studied.
The researchers describe this as a potential target for future therapy. That word—future—is essential.
Why this study matters
Diabetic retinopathy and diabetic kidney disease can both develop quietly. A person may feel well while changes are already occurring in the retina or kidneys. The PLOS study adds to the idea that these complications may have a “common soil”—shared processes such as metabolic stress, inflammation, oxidative injury, endothelial dysfunction, and now possibly ciliary dysfunction.
Understanding a shared mechanism could someday help researchers develop treatments that protect more than one organ system at a time. It may also improve scientists’ ability to identify who is at higher risk or to measure whether a treatment is reaching the right biological pathway.
But a mechanism is not the same as a medicine. Laboratory discoveries often take years to move from cells and animal models to human studies. Some do not translate at all, because human disease is more complex, doses cannot be safely reproduced, or an intervention has unexpected effects in other tissues.
The current standard: protect vision before symptoms appear
The American Diabetes Association’s 2026 Standards of Care recommend a comprehensive dilated eye examination at the time of type 2 diabetes diagnosis. If one or more annual examinations are normal and glycemic indicators are at goal, screening every one to two years may be considered for some people. If retinopathy is present, follow-up is generally at least annual and may be more frequent when disease is progressing or sight-threatening.
This guidance exists because vision-threatening disease may not cause noticeable symptoms early. Blurry vision, floaters, dark spots, distorted lines, or sudden changes in vision should prompt timely clinical attention. But waiting for symptoms is not a screening strategy.
Technology can help expand access. Retinal photography and validated artificial-intelligence tools can support screening in some settings. Still, a comprehensive examination remains necessary when images are inadequate or an abnormality needs specialist evaluation.
The current standard: protect kidneys before symptoms appear
Kidney disease can also progress without obvious warning signs. The ADA recommends at least annual testing of urine albumin-to-creatinine ratio and estimated glomerular filtration rate for adults with type 2 diabetes. More frequent monitoring is recommended once chronic kidney disease is present.
Those two tests answer different questions. Urine albumin can signal kidney damage, while estimated glomerular filtration rate helps assess how well the kidneys are filtering. Results need clinical interpretation because albumin levels and eGFR can vary, and a single abnormal test does not always tell the whole story.
The ADA Standards and KDIGO guideline support individualized management of glucose, blood pressure, cholesterol, and kidney risk. For selected patients, clinician-directed medicines may help reduce kidney or cardiovascular risk. The right treatment depends on kidney function, other conditions, medication tolerance, and the person’s goals.
Prevention is a care system, not a single behavior
It is easy to hear “high glucose can harm the eyes and kidneys” and respond with blame. That response is neither accurate nor useful. Blood glucose is influenced by physiology, medication access, food access, sleep, stress, illness, work schedules, financial pressure, and many other factors.
The new cilia research is a reason for optimism about future science. But it also reinforces an older truth: diabetes complications are interconnected, and care works best when it protects the whole person rather than chasing one number.
Diabetes Reversal Group believes type 2 diabetes care is strongest when it addresses the whole person—food, movement, sleep, stress, support systems, and ongoing clinical monitoring.
By: Dr. Jeffrey Hockings, CEO/Founder & Kristine Burke, MD, Chief Medical Officer
Do not start, stop, or change diabetes medication without guidance from the clinician managing your care. Do not use experimental compounds marketed online to try to treat diabetic eye or kidney disease.